tiprankstipranks
Trending News
More News >

EVE Health Group Advances in Women’s Health with First Order of Dyspro™

Story Highlights
  • EVE Health Group has submitted its first commercial order for Dyspro™, targeting dysmenorrhoea.
  • The product aims to capture a share of the growing USD 20 billion dysmenorrhoea treatment market by 2035.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
EVE Health Group Advances in Women’s Health with First Order of Dyspro™

Don’t Miss TipRanks’ Half-Year Sale

EVE Health Group Limited ( (AU:EVE) ) just unveiled an update.

EVE Health Group Limited has submitted its first commercial purchase order for Dyspro™, a proprietary cannabinoid-based product designed to alleviate dysmenorrhoea, marking a significant milestone in its operational expansion into prescription pharmaceuticals. The product is set to be manufactured in Australia and distributed through a network of authorized prescribers, with the company actively seeking distribution partners to ensure timely and compliant delivery. This development positions EVE to capitalize on the growing global market for dysmenorrhoea treatments, projected to reach USD 20 billion by 2035, and addresses a significant unmet need in women’s health.

More about EVE Health Group Limited

EVE Health Group Limited operates in the pharmaceutical industry, focusing on the development and distribution of cannabinoid-based pharmaceutical products. The company is expanding its market focus to include prescription pharmaceuticals, particularly targeting women’s health issues such as dysmenorrhoea.

Average Trading Volume: 756,893

Technical Sentiment Signal: Sell

Current Market Cap: A$8.62M

For an in-depth examination of EVE stock, go to TipRanks’ Overview page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1